I hope everyone had a great holiday and is ready for 2014. It has not been a stellar start for the market or biotechs, which is a little worrisome but it is still early. I have been arguing that the best tell for biotechs will be the price action from the JPM healthcare conference. I […]
Week’s Option Activity (11/18~11/21)
The following stocks had notable activity in their options during the past week(s): $HZNP (11/18): 1,632 FEB14 6.0 strike Calls (stock at $4.47) were purchased for 0.95 or $155,040. Buyer makes money if stock trades north of $6.95 by expiration. $NWBO (11/18): 250 APR14 7.5 strike Calls (stock at $5.71) were sold for 1.05 or […]
MYGN – To Myriad Investors – Your Risks are MyRisk
Co-Author: Dr. Tro Kalayjian Myriad (NASDAQ:MYGN) is a molecular diagnostics company that focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests in the United States. Their most well-known tests include BRACAnalysis/ BART, which are tests for hereditary breast and ovarian cancer, and COLARIS, another hereditary cancer test for colon […]
August 29- EOD
We got a trickle of some interesting biotech news but still nothing dramatic. I suspect that the pace will increase in September as the summer ends and the fall healthcare conference season begins. 1. PCYC announced the acceptance of the NDA for previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small […]
July 19- EOD
Really seemed like a quiet summer day to end the week. Not much to talk about but a couple of follow up notes from earlier discussions. 1. To continue from my MYGN notes from yesterday, it was confirmed from LH that they will be in the BRCA market. This just builds on the bear case […]
July 18- EOD
Not a ton of news today, so this will be a little bit of a short update but some company specific news with CELG. Outside of that there was the IPO mania that might very well be peaking. I am not convinced that we are in a complete bubble simply because everyone is calling it […]
June 14- Midday
This is midday today as I will be out of my office for the rest of the day. So an early surprise. A very odd day today in the market. Biotechs really seemed to lag for some reason even when the market was not a real drag. Let’s see how we end the day. 1. […]
June 13- EOD
Was a quiet day on the news front, so I will keep this short(er). I am just getting a sneaking suspicion that we are heading into another period where macro rules and biotechs will have a tough sledding but they have been resilient so far but I would be careful. Even when the market reversed, […]
